Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am Heart J ; 231: 128-136, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33045224

RESUMEN

The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain. DESIGN: RIVER was an academic-led, multicenter, open-label, randomized, non-inferiority trial with blinded outcome adjudication that enrolled 1005 patients from 49 sites in Brazil. Patients with a bioprosthetic mitral valve and atrial fibrillation or flutter were randomly assigned (1:1) to rivaroxaban 20 mg once daily (15 mg in those with creatinine clearance <50 mL/min) or dose-adjusted warfarin (target international normalized ratio 2.0-30.); the follow-up period was 12 months. The primary outcome was a composite of all-cause mortality, stroke, transient ischemic attack, major bleeding, valve thrombosis, systemic embolism, or hospitalization for heart failure. Secondary outcomes included individual components of the primary composite outcome, bleeding events, and venous thromboembolism. SUMMARY: RIVER represents the largest trial specifically designed to assess the efficacy and safety of a direct oral anticoagulant in patients with bioprosthetic mitral valves and atrial fibrillation or flutter. The results of this trial can inform clinical practice and international guidelines.


Asunto(s)
Fibrilación Atrial/complicaciones , Aleteo Atrial/complicaciones , Bioprótesis , Inhibidores del Factor Xa/uso terapéutico , Prótesis Valvulares Cardíacas , Válvula Mitral , Rivaroxabán/uso terapéutico , Trombosis/prevención & control , Administración Oral , Aspirina/administración & dosificación , Bioprótesis/efectos adversos , Brasil , Causas de Muerte , Creatinina/metabolismo , Embolia , Inhibidores del Factor Xa/administración & dosificación , Inhibidores del Factor Xa/efectos adversos , Prótesis Valvulares Cardíacas/efectos adversos , Hemorragia/inducido químicamente , Hospitalización , Humanos , Ataque Isquémico Transitorio , Rivaroxabán/administración & dosificación , Rivaroxabán/efectos adversos , Tamaño de la Muestra , Accidente Cerebrovascular , Procedimientos Quirúrgicos Operativos , Trombosis/etiología , Resultado del Tratamiento , Warfarina/administración & dosificación , Warfarina/efectos adversos , Warfarina/uso terapéutico
2.
J Biomol Struct Dyn ; 41(6): 2555-2573, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-35132947

RESUMEN

Trypanosoma cruzi is a protozoan transmitted by the insect Triatoma infestans, popularly known as kissing bug. This protozoan causes the Chagas disease, a Neglected Tropical Disease. This study aimed to investigate, through DFT method and B3LYP hybrid functional, the physicochemical, pharmacokinetic, and pharmacodynamic properties of the alkaloids present in the leaves of the species Pilocarpus microphyllus (jaborandi) as a potential inhibitory activity on the protease sterol 14α-demethylase of T. cruzi associated with the techniques of molecular docking, molecular dynamics, MM-PBSA and ADMET predictions. The molecules of isopilosine, epiisopiloturine, epiisopilosine, and pilosine showed up the lowest binding energies by molecular docking, good human intestinal absorption, low penetration in the blood-brain barrier, antiprotozoal and anticarcinogenic activities in ADMET studies. It has been observed a better binding affinity of the sterol 14α-demethylase protease with isopilosine in molecular dynamics and MM-PBSA studies, which indicates it as a potential drug candidate for Chagas disease.Communicated by Ramaswamy H. Sarma.


Asunto(s)
Alcaloides , Enfermedad de Chagas , Pilocarpus , Trypanosoma cruzi , Humanos , Pilocarpus/química , Simulación del Acoplamiento Molecular , Péptido Hidrolasas , Esteroles , Alcaloides/química , Enfermedad de Chagas/tratamiento farmacológico , Endopeptidasas
3.
Front Neurosci ; 9: 506, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26903799

RESUMEN

OBJECTIVES: Surgical stress induces alterations on sympathovagal balance that can be determined through assessment of blood pressure variability. Coronary artery bypass graft surgery (CABG) is associated with postoperative respiratory depression. In this study we aimed at investigating ICU blood pressure variability and other perioperative parameters that could predict the nadir of postoperative respiratory function impairment. METHODS: This prospective observational study evaluated 44 coronary artery disease patients subjected to coronary artery bypass surgery (CABG) with cardiopulmonary bypass (CPB). At the ICU, mean arterial pressure (MAP) was monitored every 30 min for 3 days. MAP variability was evaluated through: standard deviation (SD), coefficient of variation (CV), variation independent of mean (VIM), and average successive variability (ASV). Respiratory function was assessed through maximal inspiratory (MIP) and expiratory (MEP) pressures and peak expiratory flow (PEF) determined 1 day before surgery and on the postoperative days 3rd to 7th. Intraoperative parameters (volume of cardioplegia, CPB duration, aortic cross-clamp time, number of grafts) were also monitored. RESULTS: Since, we aimed at studying patients without confounding effects of postoperative complications on respiratory function, we had enrolled a cohort of low risk EuroSCORE (European System for Cardiac Operative Risk Evaluation) with < 2. Respiratory parameters MIP, MEP, and PEF were significantly depressed for 4-5 days postoperatively. Of all MAP variability parameters, the ASV had a significant good positive Spearman correlation (rho coefficients ranging from 0.45 to 0.65, p < 0.01) with the 3-day nadir of PEF after cardiac surgery. Also, CV and VIM of MAP were significantly associated with nadir days of MEP and PEF. None of the intraoperative parameters had any correlation with the postoperative respiratory depression. CONCLUSIONS: Variability parameters ASV, CV, and VIM of the MAP monitored at ICU may have predictive value for the depression of respiratory function after cardiac surgery as determined by peak expiratory flow and maximal expiratory pressure. ClinicalTrials.gov Identifier: NCT02074371.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA